Argenica Therapeutics

Argenica Therapeutics

Argenica Therapeutics is developing a novel peptide drug, ARG-007, that has shown great results in preclinical models of ischaemic stroke and is now being tested in a Phase 2 trial in ischaemic stroke patients in hospitals across Australia. The way the drug was discovered and the mechanism by which it works to reduce brain injury gives a solid scientific basis for progressing this drug through clinical trials. Joining us to talk more about the discovery of ARG-007 and its unique mechanism of action is Argenica’s Chief Scientific Officer, and inventor of ARG-007, Prof Bruno Meloni. Joining Bruno is Argenica’s CEO Dr Liz Dallimore.